2019 Ophthalmic Drugs Market Research Report Countries, Growth Rate, Market Latest Trends, Future Technologies Forecast to 2024


The primary goal of this Ophthalmic Drugs Market report is to maintain the record of Unusual growth strategies adopted by various companies are creating new standards for competition in the Ophthalmic Drugs market. Businesses around the world are aiming at increasing their profit margin and establishing a stronghold in the market. The impact of prevailing regulatory scenario on both regional and worldwide Ophthalmic Drugs market is provided in detail in the report.

Get Sample Copy of Ophthalmic Drugs Market Report @

Key Market Trends:

The Dry Eye Segment under Drug Class is Expected to Account for the Largest Market Share during the Forecast Period

Dry eye disease (DED) is a multi-factorial disease of the tear film and ocular surface that results in ocular discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is a generally under-diagnosed clinical condition, as patients often attribute the experienced DED symptoms to aging, and hence, it remains an under-researched condition in the low- and middle-income countries. The prevalence of DED can be as high as 30% of the total population. In the last decade, only one drug was approved for the treatment of DED by the US Food and Drug Administration (FDA) (i.e., Restasis by Allergan Inc.). DED is a major public health problem, the burden of which is likely to increase due to the increasing proportion of the aging population and the adoption of modern lifestyle. Dry eye disease is a common ocular disorder in the elderly and a frequent cause of eye care visits among this age group. The total annual cost of dry eye drug to the US economy can be more than USD 55 billion. Thus, the development of new drug treatments for dry eye is essential for both the dry eye patients and the ophthalmic industry. Many drugs are in the pipeline for dry eye diseases. The increasing prevalence of DED, approval of drugs for its treatment, and government initiatives to eradicate it are the main factors spurring the growth of the market studied.

The Asia-Pacific Segment is Expected to Account for the Fastest Growth Rate

The ophthalmic drugs market is expanding and growing, ly. The market has been witnessing an especially exponential growth in the Asia-Pacific region. Glaucoma and tear substitute (for dry eye) drugs are the leading products in Asia-Pacific. India is likely to be among the top three pharmaceutical markets by incremental growth and the sixth-largest market, ly, in absolute size, according to the Clinical and Experimental Vision and Eye Research, India, 2018. Increase in the number of middle-class households, advancement in medical infrastructure, and the increasing penetration of health insurance in the country are likely to play a significant role in influencing this growth. According to the National Health Policy (NHP), in India, glaucoma is the leading cause of irreversible blindness with at least 12 million people have affected and nearly 1.2 million people having blinded from the disease. More than 90% of the cases of glaucoma remain undiagnosed in the country.

Moreover, the prevalence of glaucoma increases with age. Thus, the rising prevalence of glaucoma and an increase in healthcare expenditure are spurring the growth of the ophthalmic drugs market in India. Furthermore, the country’s government is also playing an important role, since the cost of glaucoma treatment in India is one of the lowest in the world.

Ophthalmic Drugs Market Covers Key Players:

  • Aerie Pharmaceuticals Inc.
  • Allergan
  • Bausch Health Companies Inc.
  • Bayer AG
  • F. Hoffmann
  • La Roche Ltd
  • Hoya Corporation
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co. Ltd

    Ask for Discount at

    Geographical Landscape:

    This Report Focuses on the Ophthalmic Drugs in the market, especially in North America, China, Europe, Japan, Southeast Asia, India. This report categorizes the market based on manufacturers, regions, type, and application

    Market Overview:

  • The major factors attributed to the growth of the ophthalmic drugs market include the increasing incidence and prevalence of eye-related disorders, rising R&D activities pertaining to the development of novel drugs, and increasing focus on developing combination therapies.
  • The increasing prevalence of eye diseases is increasing the demand for ophthalmic drugs, ly. In many developed and developing countries, eye conditions have emerged as potential threats to the status of sight of their populations. The increase in the prevalence of diabetes in various countries has caused diabetic retinopathy to be added to the priority list. Glaucoma, an eye disease known for centuries, remains on the public health agenda due to difficulties in its early diagnosis and frequent necessity of life-long treatment. According to the WHO, in 2018, it was estimated that approximately 1.3 billion people were living with some form of vision impairment, 188.5 million people had a mild vision impairment, 217 million had moderate to severe vision impairment, and 36 million people are blind. ly, the leading causes of vision impairment are uncorrected refractive errors and cataracts, and the majority of people with vision impairment are over the age of 50 years. According to the WHO, chronic eye diseases are the number one cause of vision loss, with the top two causes being unoperated cataracts and uncorrected refractive errors. The former is the leading cause in countries with low- or middle-incomes. More than 80% of the vision impairments are curable or preventable, which means that these drugs are required for the management of the diseases. Hence, the rising incidence of eye-related disorders is projecting a great impact on the growth of market studied.<

    Report Highlights:

    – The report provides a detailed analysis on current and future market trends to identify the investment opportunities

    – Market forecasts till 2024, using estimated market values as the base numbers

    – Key market trends across the business segments, Regions and Countries

    – Key developments and strategies observed in the market

    – Market Dynamics such as Drivers, Restraints, Opportunities and other trends

    – In-depth company profiles of key players and upcoming prominent players

    – Growth prospects among the emerging nations through 2024

    – Ophthalmic Drugs Market opportunities and recommendations for new investments

    Price Of Report: $ 4250 (SUL)

    Purchase Ophthalmic Drugs Market Report @

    Detailed TOC of Ophthalmic Drugs Market Research Report 2019 – 2024:

    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study



    4.1 Market Overview
    4.2 Market Drivers
    4.2.1 Increasing Incidence and Prevalence of Eye-related Disorders
    4.2.2 Rising R&D Pertaining to the Development of Novel Drugs
    4.2.3 Increasing Focus on Developing Combination Therapies
    4.3 Market Restraints
    4.3.1 Loss of Patent Protection for Popular Drugs
    4.3.2 Lack of Health Insurance in the Developing Countries
    4.4 Porter’s Five Forces Analysis
    4.4.1 Threat of New Entrants
    4.4.2 Bargaining Power of Buyers/Consumers
    4.4.3 Bargaining Power of Suppliers
    4.4.4 Threat of Substitute Products
    4.4.5 Intensity of Competitive Rivalry

    5.1 By Drug Class
    5.1.1 Anti-glaucoma Drug
    5.1.2 Dry eye Drug
    5.1.3 Ophthalmic Anti-allergy/Inflammatory
    5.1.4 Retinal Drug
    5.1.5 Anti-infective Drugs
    5.1.6 Other Drugs
    5.2 By Product Type
    5.2.1 OTC Drug
    5.2.2 Prescription Drug
    5.3 Geography
    5.3.1 North America US Canada Mexico
    5.3.2 Europe Germany UK France Italy Spain Rest of Europe
    5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
    5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
    5.3.5 South America Brazil Argentina Rest of South America

    6.1 Company Profiles
    6.1.1 Aerie Pharmaceuticals Inc.
    6.1.2 Allergan
    6.1.3 Bausch Health Companies Inc.
    6.1.4 Bayer AG
    6.1.5 F. Hoffmann-La Roche Ltd
    6.1.6 Hoya Corporation
    6.1.7 Novartis AG
    6.1.8 Pfizer Inc.
    6.1.9 Regeneron Pharmaceuticals Inc.
    6.1.10 Santen Pharmaceutical Co. Ltd


    About Industry Research:

    Industry Research is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market, dedicated to bringing you an ingenious concoction of data parameters.

    Contact Us:

    Name: Ajay More

    Organization: Industry Research

    Phone: +44 20 3239 8187 / +14242530807

    Email: [email protected]

    Our latest Report: Global Animal Genetics Market 2019: Comprehensive Insight by Growth Rate, Global Trends, Industry Status, Key Players Forecast till 2025